GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » PB Ratio

Kaleido Biosciences (Kaleido Biosciences) PB Ratio : 0.00 (As of Apr. 27, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Kaleido Biosciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-27), Kaleido Biosciences's share price is $0.0001. Kaleido Biosciences's Book Value per Share for the quarter that ended in Dec. 2021 was $0.25. Hence, Kaleido Biosciences's PB Ratio of today is 0.00.

The historical rank and industry rank for Kaleido Biosciences's PB Ratio or its related term are showing as below:

KLDO's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.38
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Kaleido Biosciences PB Ratio Historical Data

The historical data trend for Kaleido Biosciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaleido Biosciences PB Ratio Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PB Ratio
Get a 7-Day Free Trial - - 3.09 15.99 9.60

Kaleido Biosciences Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.99 4.80 6.30 7.96 9.60

Competitive Comparison of Kaleido Biosciences's PB Ratio

For the Biotechnology subindustry, Kaleido Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaleido Biosciences's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's PB Ratio falls into.



Kaleido Biosciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Kaleido Biosciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2021)
=0.0001/0.249
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Kaleido Biosciences  (OTCPK:KLDO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Kaleido Biosciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Kaleido Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaleido Biosciences (Kaleido Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.
Executives
Alison S Long officer: Chief Medical Officer KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Van Hylckama Vlieg Johan officer: Chief Scientific Officer C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Daniel L Menichella director, officer: Chief Executive Officer 79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709
Kyriazi Theo Melas director 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Nutritional Health Ltp Fund General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Anne Prener director C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
William E. Duke officer: CHIEF FINANCIAL OFFICER C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Richard William Scalzo officer: Principal Accounting Officer 25 ALBERTA LANE, HOLLISTON MA 01746
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Jerald Korn officer: General Counsel 128 GORDON RD, NEWTON MA 02468
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Michael W Bonney director, officer: Executive Chair 65 HAYDEN AVE, LEXINGTON MA 02421
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142

Kaleido Biosciences (Kaleido Biosciences) Headlines

From GuruFocus

Kaleido Biosciences Reports Second Quarter 2021 Financial Results

By Marketwired Marketwired 08-11-2021